Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 33, Issue 6, 2010, Pages

  Satoh, Masaaki ^a   Saito, Makoto ^a   Tanaka, Kohsuke ^a   Iwanaga, Sumako ^a   Ali, Salem Nagla Elwy Salem ^a   Seki, Takahiro ^c   Okada, Seiji ^a   Kohara, Michinori ^b   Harada, Shinji ^a   Kai, Chieko ^c   Tsukiyama Kohara, Kyoko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

E1; E2; HCV; Human PBL; MV; NOD Scid Jak3null mouse

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; JANUS KINASE 3; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKOCYTE; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PROTEIN EXPRESSION; SCID MOUSE; SPLEEN CELL; VIRUS RECOMBINANT;

ANIMALS; BLOTTING, WESTERN; CALLITHRIX; CELL LINE; COCULTURE TECHNIQUES; CYTOPATHOGENIC EFFECT, VIRAL; FLOW CYTOMETRY; HEPATITIS C; HUMANS; LEUKOCYTES, MONONUCLEAR; MEASLES VIRUS; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; SPLEEN; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS; MEASLES VIRUS; MUS;

EID: 78650196441     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2010.02.006     Document Type: Article

References (40)

1. Di Bisceglie A.M., Carithers R.L., Gores G.J. Hepatocellular carcinoma. Hepatology 1998, 28(4):1161-1165.
2. Hayashi J., et al. Hepatitis C virus and hepatocarcinogenesis. Intervirology 1999, 42(2-3):205-210.
3. Michielsen P.P., Francque S.M., van Dongen J.L. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005, 3:27.
4. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat, 1999;6(1):35-47.
5. Zoulim F., et al. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003, 13(1):57-68.
6. Bruchfeld A., et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001, 8(4):287-292.
7. Mazzella G., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996, 24(2):141-147.
8. Kohara M., et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. J Infect Dis 1995, 172(4):934-938.
9. Nakamura H., et al. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus. Hepatogastroenterology 2002, 49(47):1373-1376.
10. Bukh J., et al. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 2001, 44(2-3):132-142.
11. Bowen D.G., Walker C.M. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005, 201(11):1709-1714.
12. Lechmann M., Liang T.J. Vaccine development for hepatitis C. Semin Liver Dis 2000, 20(2):211-226.
13. Combredet C., et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003, 77(21):11546-11554.
14. Naniche D., et al. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 2004, 190(8):1387-1395.
15. Ovsyannikova I.G., et al. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003, 10(3):411-416.
16. Brandler S., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007, 1(3):e96.
17. Brandler S., Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 2008, 31(2-3):271-291.
18. Guerbois M., et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009, 388(1):191-203.
19. Liniger M., et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009, 27(25-26):3299-3305.
20. Lorin C., et al. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 2005, 23(36):4463-4472.
21. Lorin C., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004, 78(1):146-157.
22. Cantarella G., et al. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009, 27(25-26):3385-3390.
23. Liniger M., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 2008, 26(17):2164-2174.
24. Despres P., et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(2):207-214.
25. Radecke F., et al. Rescue of measles viruses from cloned DNA. EMBO J 1995, 14(23):5773-5784.
26. Okada S., et al. Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34+ cells. Int J Hematol 2008, 88(5):476-482.
27. Hattori S., et al. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 2009, 53(9):3887-3893.
28. Kobune F., Sakata H., Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 1990, 64(2):700-705.
29. Tsukiyama-Kohara K., et al. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem 2004, 279(15):14531-14541.
30. Yoneda M., et al. Rinderpest virus phosphoprotein gene is a major determinant of species-specific pathogenicity. J Virol 2004, 78(12):6676-6681.
31. Op De Beeck A., Cocquerel L., Dubuisson J. Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 2001, 82(Pt 11):2589-2595.
32. Beyene A., et al. Hepatitis C virus envelope glycoproteins and potential for vaccine development. Vox Sang 2002, 83(Suppl 1):27-32.
33. Seong Y.R., et al. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. Vaccine 2001, 19(20-22):2955-2964.
34. Stamataki Z., et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007, 25(45):7773-7784.
35. Ohno S., et al. Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. J Virol 2007, 81(4):1650-1659.
36. Sellin C.I., et al. High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice. J Virol 2006, 80(13):6420-6429.
37. Falkowska E., et al. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol 2007, 81(15):8072-8079.
38. Helle F., et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007, 81(15):8101-8111.
39. Jackson P., et al. Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol 1997, 51(1):67-79.
40. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36(5 Suppl 1):S21-S29.